bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval
pharmaphorum
AUGUST 18, 2022
million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 It slashed its workforce by 30% to reduce cash burn and extend its funded operations into the first half of 2023, so investors will be looking for signs of take-up of Zynteglo in the coming months.
Let's personalize your content